Table 1 Correlation of nm23-H1 mRNA level and metastatic potential in human cancers

Cancer types	Patient #	^aMethod	^bCorrelation	References
Bladder cancer	22	NB, SH	None	⁵⁷
Brain cancer	27	NB	None	⁵⁸
Breast cancer	27–71	ISH, NB	Neg.	^{59, 60}
	153	NB, SH	None	⁶¹
Cervical cancer	98	NB	Neg.	⁶²
Colorectal cancer	21–52	NB, PCR	Neg.	^{63, 64}
	18–61	NB	Pos.	^{65, 66}
	22–43	DIFF-PCR, RPA	None	^{67, 68}
Gastric cancer	19–31	NB	Neg.	^{69, 70}
	23	NB	None	⁷¹
Head and neck cancer	20–78	ISH, RT-PCR, qPCR	Neg.	^{72, 73}
Kidney cancer	16	NB, SH	Pos.	⁵⁷
Leukemia	47	NB, RT-PCR	Pos.	⁷⁴
Liver cancer	17–30	NB, RT-qPCR	Neg.	^{75, 76, 77}
	18	RT-qPCR	Pos.	⁷⁸
Lung cancer	37	NB	Pos.	⁷⁹
	10	RT-PCR	None	⁸⁰
Lymphoma	106	NB	Pos.	⁸¹
Melanoma	30–33	NB	Neg.	^{82, 83}
Neuroblastoma	75	NB	Pos.	⁸
Ovarian cancer	48–106	NB, RT-PCR	Neg.	^{84, 85, 86, 87}
	45	NB	Pos.	⁸⁸
Pancreatic cancer	81	ISH, NB	Neg.	⁸⁹
Peripheral synovial sarcoma	31	RT-PCR+SH	Pos.	⁹⁰
Prostate cancer	29	NB	Pos.	⁹¹
Thyroid cancer	54	RT-PCR	Neg.	⁹²
	39	NB	Pos.	⁹³

^aDIFF-PCR, differential polymerase chain reaction; ISH, in-situ hybridization; NB, Northern blotting; PCR, polymerase chain reaction; qPCR, real-time quantitative PCR; RPA, ribonuclease protection assay; RT-PCR, reverse transcription PCR; RT-qPCR, reverse transcription qPCR; SH, slot blot hydridization.
^bPositive, negative, or no correlation is indicated as Pos., Neg. or None, respectively.

Quick links

Search